Nephrogene / supplemental data

Supplemental data:

Mycophenolate Mofetil use is associated with prolonged graft survival after kidney transplantation

A. Kainz^1,2, G. Heinze³, R. Korbély¹, C. Schwarz¹, R. Oberbauer^1,2,4

1- Department of Nephrology, KH Elisabethinen, Linz, Austria 2- Department of Nephrology, Medical University Vienna, Austria 3- Core Unit of Medical Statistics and Informatics, Medical University Vienna, Vienna 4- Austrian Dialysis and Transplant Registry, Austria

All supplemental data are available for download as a single PDF document.

STROBE-Checklist: PDF document.

TABLES

FIGURES

Webtable 1
List of all variables in the database used for analysis
Webfigure 1
Kaplan-Meier plot of actual graft survival counting graft loss and death as event. The numbers below the x-axis refer to the subjects at risk at each time point. The p-value was derived from a log-rank test.

Webfigure 2
Kaplan – Meier plot of patient survival. The numbers below the x-axis show the patients at risk at two years intervals. The p-value was derived from a log-rank test.

Webtable 2
Functional graft survival

Parameters used for propensity score model for functional graft survival
Webfigure 3
Functional graft survival

Distribution of propensity score for functional graft survival of the groups MMF and AZA.

Webtable 3
Functional graft survival

Summary of the results derived from the five different analytical strategies analyzing the hazard of functional graft loss in the AZA vs MMF patients adjusted for several covariables.

Webtable 4
Actual graft survival

Parameters used for propensity score model for actual graft survival
Webfigure 4
Actual graft survival

Distribution of propensity score for actual graft survival of the groups MMF and AZA.

Webtable 5
Actual graft survival

Summary of the results derived from the five different analytical strategies analyzing the hazard of actual graft loss in the AZA vs. MMF patients adjusted for several covariables.

Webtable 6
Patient survival

Parameters used for propensity score model patient survival
Webfigure 5
Patient survival

Distribution of propensity score for patient survival of the groups MMF and AZA.

Webtable 7
Patient survival

Summary of the results derived from the five different analytical strategies analyzing the hazard of mortality in the AZA vs. MMF patients adjusted for several covariables.

Webfigure 6
Schoenfeld residuals
Functional graft survival (CCO analysis)

Webfigure 7
Schoenfeld residuals
Actual graft survival (CCO analysis)

Webfigure 8
Schoenfeld residuals
Patient survival (CCO analysis)

TABLES		FIGURES
	Webtable 1 List of all variables in the database used for analysis		Webfigure 1 Kaplan-Meier plot of actual graft survival counting graft loss and death as event. The numbers below the x-axis refer to the subjects at risk at each time point. The p-value was derived from a log-rank test.
			Webfigure 2 Kaplan – Meier plot of patient survival. The numbers below the x-axis show the patients at risk at two years intervals. The p-value was derived from a log-rank test.
	Webtable 2 Functional graft survival Parameters used for propensity score model for functional graft survival		Webfigure 3 Functional graft survival Distribution of propensity score for functional graft survival of the groups MMF and AZA.
	Webtable 3 Functional graft survival Summary of the results derived from the five different analytical strategies analyzing the hazard of functional graft loss in the AZA vs MMF patients adjusted for several covariables.
	Webtable 4 Actual graft survival Parameters used for propensity score model for actual graft survival		Webfigure 4 Actual graft survival Distribution of propensity score for actual graft survival of the groups MMF and AZA.
	Webtable 5 Actual graft survival Summary of the results derived from the five different analytical strategies analyzing the hazard of actual graft loss in the AZA vs. MMF patients adjusted for several covariables.
	Webtable 6 Patient survival Parameters used for propensity score model patient survival		Webfigure 5 Patient survival Distribution of propensity score for patient survival of the groups MMF and AZA.
	Webtable 7 Patient survival Summary of the results derived from the five different analytical strategies analyzing the hazard of mortality in the AZA vs. MMF patients adjusted for several covariables.
			Webfigure 6 Schoenfeld residuals Functional graft survival (CCO analysis)
			Webfigure 7 Schoenfeld residuals Actual graft survival (CCO analysis)
			Webfigure 8 Schoenfeld residuals Patient survival (CCO analysis)

Supplemental data:

Mycophenolate Mofetil use is associated with prolonged graft survival after kidney transplantation

A. Kainz1,2, G. Heinze3, R. Korbély1, C. Schwarz1, R. Oberbauer1,2,4

A. Kainz^1,2, G. Heinze³, R. Korbély¹, C. Schwarz¹, R. Oberbauer^1,2,4